tenofovir alafenamide TAF
Selected indexed studies
- Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (Expert Rev Anti Infect Ther, 2018) [PMID:29338458]
- Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). (Biochem Pharmacol, 2016) [PMID:27133890]
- Tenofovir Alafenamide. (Ann Pharmacother, 2016) [PMID:27465879]
_Worker-drafted node — pending editorial review._
Connections
tenofovir alafenamide TAF is a side effect of
Sources
- Tenofovir Alafenamide. (2016) pubmed
- Tenofovir alafenamide fumarate. (2022) pubmed
- Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. (2024) pubmed
- Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (2018) pubmed
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) pubmed
- Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. (2018) pubmed
- Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). (2016) pubmed
- From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. (2024) pubmed
- Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes. (2025) pubmed
- Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting. (2021) pubmed